Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis

Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis

<p>Abstract</p> <p>Background</p> <p>The plasma protein α<sub>2</sub>-antiplasmin (α<sub>2</sub>AP) is cross-linked to fibrin in blood clots by the transglutaminase factor XIIIa, and in that location retards clot lysis. Competition for this effec...

Full description

Bibliographic Details
Main Authors: Gataiance Sharon, Eltringham-Smith Louise J, Sheffield William P, Bhakta Varsha
Format: Article
Language:English
Published: BMC 2009-03-01
Series:BMC Biotechnology
Online Access:http://www.biomedcentral.com/1472-6750/9/15
id doaj-10245e9da0ed41cdb52ba1120af921df
record_format Article
spelling doaj-10245e9da0ed41cdb52ba1120af921df2020-11-25T03:55:10ZengBMCBMC Biotechnology1472-67502009-03-01911510.1186/1472-6750-9-15Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysisGataiance SharonEltringham-Smith Louise JSheffield William PBhakta Varsha<p>Abstract</p> <p>Background</p> <p>The plasma protein α<sub>2</sub>-antiplasmin (α<sub>2</sub>AP) is cross-linked to fibrin in blood clots by the transglutaminase factor XIIIa, and in that location retards clot lysis. Competition for this effect could be clinically useful in patients with thrombosis. We hypothesized that fusion of N-terminal portions of α<sub>2</sub>-antiplasmin to human serum albumin (HSA) and production of the chimeric proteins in <it>Pichia pastoris </it>yeast would produce a stable and effective competitor protein.</p> <p>Results</p> <p>Fusion protein α<sub>2</sub>AP(13-42)-HSA was efficiently secreted from transformed yeast and purified preparations contained within a mixed population the full-length intact form, while fusions with longer α<sub>2</sub>AP moieties were inefficiently secreted and/or degraded. The α<sub>2</sub>AP(13-42)-HSA protein, but not recombinant HSA, was cross-linked to both chemical lysine donors and fibrin or fibrinogen by factor XIIIa, although with less rapid kinetics than native α<sub>2</sub>AP. Excess α<sub>2</sub>AP(13-42)-HSA competed with α<sub>2</sub>AP for cross-linking to chemical lysine donors more effectively than a synthetic α<sub>2</sub>AP(13-42) peptide, and reduced the α<sub>2</sub>AP-dependent resistance to fibrinolysis of plasma clots equally effectively as the peptide. Native α<sub>2</sub>AP was found in <it>in vivo </it>clots in rabbits to a greater extent than α<sub>2</sub>AP(13-42), however.</p> <p>Conclusion</p> <p>In this first report of transfer of transglutamination substrate status from one plasma protein to another, fusion protein α<sub>2</sub>AP(13-42)-HSA was shown to satisfy initial requirements for a long-lasting, well-tolerated competitive inhibitor of α<sub>2</sub>-antiplasmin predicted to act in a clot-localized manner.</p> http://www.biomedcentral.com/1472-6750/9/15
collection DOAJ
language English
format Article
sources DOAJ
author Gataiance Sharon
Eltringham-Smith Louise J
Sheffield William P
Bhakta Varsha
spellingShingle Gataiance Sharon
Eltringham-Smith Louise J
Sheffield William P
Bhakta Varsha
Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
BMC Biotechnology
author_facet Gataiance Sharon
Eltringham-Smith Louise J
Sheffield William P
Bhakta Varsha
author_sort Gataiance Sharon
title Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
title_short Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
title_full Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
title_fullStr Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
title_full_unstemmed Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
title_sort addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
publisher BMC
series BMC Biotechnology
issn 1472-6750
publishDate 2009-03-01
description <p>Abstract</p> <p>Background</p> <p>The plasma protein α<sub>2</sub>-antiplasmin (α<sub>2</sub>AP) is cross-linked to fibrin in blood clots by the transglutaminase factor XIIIa, and in that location retards clot lysis. Competition for this effect could be clinically useful in patients with thrombosis. We hypothesized that fusion of N-terminal portions of α<sub>2</sub>-antiplasmin to human serum albumin (HSA) and production of the chimeric proteins in <it>Pichia pastoris </it>yeast would produce a stable and effective competitor protein.</p> <p>Results</p> <p>Fusion protein α<sub>2</sub>AP(13-42)-HSA was efficiently secreted from transformed yeast and purified preparations contained within a mixed population the full-length intact form, while fusions with longer α<sub>2</sub>AP moieties were inefficiently secreted and/or degraded. The α<sub>2</sub>AP(13-42)-HSA protein, but not recombinant HSA, was cross-linked to both chemical lysine donors and fibrin or fibrinogen by factor XIIIa, although with less rapid kinetics than native α<sub>2</sub>AP. Excess α<sub>2</sub>AP(13-42)-HSA competed with α<sub>2</sub>AP for cross-linking to chemical lysine donors more effectively than a synthetic α<sub>2</sub>AP(13-42) peptide, and reduced the α<sub>2</sub>AP-dependent resistance to fibrinolysis of plasma clots equally effectively as the peptide. Native α<sub>2</sub>AP was found in <it>in vivo </it>clots in rabbits to a greater extent than α<sub>2</sub>AP(13-42), however.</p> <p>Conclusion</p> <p>In this first report of transfer of transglutamination substrate status from one plasma protein to another, fusion protein α<sub>2</sub>AP(13-42)-HSA was shown to satisfy initial requirements for a long-lasting, well-tolerated competitive inhibitor of α<sub>2</sub>-antiplasmin predicted to act in a clot-localized manner.</p>
url http://www.biomedcentral.com/1472-6750/9/15
work_keys_str_mv AT gataiancesharon additionofasequencefromasub2subantiplasmintransformshumanserumalbuminintoabloodclotcomponentthatspeedsclotlysis
AT eltringhamsmithlouisej additionofasequencefromasub2subantiplasmintransformshumanserumalbuminintoabloodclotcomponentthatspeedsclotlysis
AT sheffieldwilliamp additionofasequencefromasub2subantiplasmintransformshumanserumalbuminintoabloodclotcomponentthatspeedsclotlysis
AT bhaktavarsha additionofasequencefromasub2subantiplasmintransformshumanserumalbuminintoabloodclotcomponentthatspeedsclotlysis
_version_ 1724470356202225664

Similar Items